CTK's Q1 2026 Revenue Up 24.5% YoY but Turns to Operating Loss; Net Loss Widens to 46.2 Billion Won Due to Derivative Losses

Consolidated revenue KRW 24,453mn (+24.5% YoY), operating loss KRW 1,740mn (vs profit of KRW 369mn YoY), net loss KRW 4,623mn (vs loss of KRW 177mn YoY)
Non-operating items: derivative valuation loss KRW 3,667mn, foreign exchange gain KRW 1,648mn, etc.
CTKCLIP segment: revenue KRW 23,802mn, operating profit KRW 45mn (vs KRW 1,689mn YoY); eco-friendly and other segments continued losses
Debt ratio 84.4%, net debt ratio 24.8%, borrowings & convertible bonds KRW 49,687mn, cash KRW 13,741mn
US OTC plant (CTK OTC LABORATORIES) operational, targeting North American OTC market
Recognized KRW 1,663mn impairment loss on suspended DLS redemption; recoverability uncertain
Paid cash dividend of KRW 110 per share (differential) for FY2025; no new dividend in Q1
One lawsuit filed as plaintiff; financial impact unpredictable

ADVERTISEMENT (250px+)